- Current report filing (8-K)
January 31 2011 - 1:57PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): January 31, 2011
Manhattan
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-32639
|
|
36-3898269
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
48
Wall Street, Suite 1110
New
York, New York 10005
(Address
of principal executive offices) (Zip Code)
(212)
582-3950
(Registrant's
telephone number, including area code)
Not
applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
On
January 31, 2011 Manhattan Pharmaceuticals, Inc. announced that its company’s
Board of Directors has decided to continue development of AST-915, an orally
delivered treatment for essential tremor. Under the terms of the merger
agreement between Manhattan Pharmaceuticals, Inc. and Ariston Pharmaceuticals,
Inc., the achievement of this milestone requires the company to issue 8,828,029
shares of its common stock to debt holders and former shareholders of
Ariston.
|
Item
9.01
|
Financial
Statements and Exhibits
|
|
(d)
|
Exhibits
|
|
|
|
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
release dated January 31, 2011.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
|
MANHATTAN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date:
January 31,
2011
|
By:
|
/s/
Michael G. McGuinness
|
|
|
|
Michael
G. McGuinness
|
|
|
|
Chief
Operating and Financial Officer
|